No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
BIB Ultra Nasdaq Biotechnology Proshares
- 49.110
- +0.910+1.89%
Close Apr 22 16:00 ET
49.921High48.330Low
49.921High48.330Low16.05KVolume48.520Open48.200Pre Close795.03KTurnover1.00%Turnover Ratio--P/E (Static)1.60MShares62.40552wk High--P/B78.58MFloat Cap40.04352wk Low0.08Dividend TTM1.60MShs Float112.860Historical High0.16%Div YieldTTM3.30%Amplitude4.233Historical Low49.546Avg Price1Lot Size
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | The European Commission Has Approved AstraZeneca's Voydeya (Danicopan) As An Add-on To Ravulizumab Or Eculizumab For Paroxysmal Nocturnal Hemoglobinuria Patients Who Have Residual Hemolytic Anemia
AstraZeneca Obtains EU Approval for Voydeya as Add-on Treatment for Rare Blood Disease
AstraZeneca (AZN.L, AZN.ST) said Tuesday the European Commission approved its Voydeya as an add-on medication for the treatment of the rare blood disease paroxysmal nocturnal hemoglobinuria.
Express News | Vertex Pharmaceuticals Inc - Treefrog Will Also Receive up to $215M in Milestones
Express News | Vertex Pharmaceuticals Inc - Treefrog Is Also Eligible to Receive an Additional $540M in Clinical, Regulatory and Commercial Milestones
Express News | Vertex Pharmaceuticals Inc - Vertex Will Fund All Research and Development Costs Related to Collaboration
Express News | Vertex Pharmaceuticals Inc - Under Agreement, Treefrog Will Receive a $25M Upfront Payment, an Equity Investment From Vertex
Comments
Do you have a bullish outlook on the biotech sector for 2024? Feel free to share and discuss in the comments below.🥰 $SPDR S&P Biotech ETF(XBI.US$$Ultra Nasdaq Biotechnology Proshares(BIB.US$$iShares Biotechnology ETF(IBB.US$
5
1
Health Care Sector Update for 08/24/2022: SPRC,GKOS,BCDA
$Ultra Nasdaq Biotechnology Proshares(BIB.US$ was climbing 1.5%.
$SciSparc(SPRC.US$ rallied Wednesday, climbing over 20%, after the Israeli pharmaceuticals company said the psychedelic-based MEAI drug candidate developed with Canadian collaborator Clearmind Medicine produced a significant decrease in coccaine craving in rats compared to those in a non-treated control group during pre-clinical testing.
$Glaukos(GKOS.US$ gained 6% after We...
$SciSparc(SPRC.US$ rallied Wednesday, climbing over 20%, after the Israeli pharmaceuticals company said the psychedelic-based MEAI drug candidate developed with Canadian collaborator Clearmind Medicine produced a significant decrease in coccaine craving in rats compared to those in a non-treated control group during pre-clinical testing.
$Glaukos(GKOS.US$ gained 6% after We...
3
Read more